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Hepatocellular carcinoma (HCC) is a highly vascular tumour that expresses vascular endothelial growth factor (VEGF). Various
studies have evaluated the prognostic value of VEGF levels in HCC. Its overall test performance remains unclear, however. The aim
was to perform a systematic review and meta-analysis of prognostic cohort studies evaluating the use of VEGF as a predictor of
survival in patients with treated HCC. Eligible studies were identified through multiple search strategies. Studies were assessed for
quality using the Newcastle–Ottawa Tool. Data were collected comparing disease-free and overall survival in patients with high
VEGF levels as compared to those with low levels. Studies were pooled and summary hazard ratios were calculated. A total of 16
studies were included for meta-analysis (8 for tissue and 8 for serum). Methodological analysis indicated a trend for higher study
quality with serum studies as compared to tissue-based investigations. Four distinct groups were pooled for analysis: tissue overall
survival (n¼251), tissue disease-free survival (n¼413), serum overall survival (n¼579), and serum disease-free survival (n¼439).
High tissue VEGF levels predicted poor overall (HR¼2.15, 95% CI: 1.26–3.68) and disease-free (HR¼1.69, 95% CI: 1.23–2.33)
survival. Similarly, high serum VEGF levels predicted poor overall (HR¼2.35, 95% CI: 1.80–3.07) and disease-free (HR¼2.36, 95%
CI 1.76–3.16) survival. A high degree of inter-study consistency was present in three of four groups analysed. Tissue and serum VEGF
levels appear to have significant predictive ability for estimating overall survival in HCC and may be useful for defining prognosis in
HCC.
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Hepatocellular carcinoma (HCC) is the fifth most common type of
cancer and the third most common cause of annual cancer-related
deaths worldwide (Parkin, 2001). The incidence of HCC is
predicted to increase over the next several decades as survival in
patients with predisposing diseases, such as cirrhosis, is expected
to increase over time (El-Serag, 2002; Marrero, 2006). Because of
this, there has been great interest in evaluating factors that
influence prognosis in HCC. The most widely studied prognostic
factors are related to pathological characteristics of the neoplasm,
including tumour size, grade, stage, and vascular invasion (Tsai
et al, 2000; Mann et al, 2007; Zhou et al, 2007; Lam et al, 2008). A
variety of other potential serum prognostic markers, however,
remain to be further characterised (Mann et al, 2007).
Angiogenesis, defined as the formation of new blood vessels
from existing vasculature, is an important process regulating the
growth and development of malignancies including HCC (Sun and
Tang, 2004; Pang and Poon, 2006). The extensive hypervascularity
associated with HCC is thought to be driven in part by the pro-
angiogenic factor known as vascular endothelial growth factor
(VEGF) (Sun and Tang, 2004; Pang and Poon, 2006). Furthermore,
the invasiveness of certain HCC lesions has recently been linked to
high levels of VEGF, leading several authors to conclude that an
important relationship between VEGF and prognosis exists for
HCC (Li et al, 1998; Kanda et al, 2008). Conflicting data, however,
have emerged regarding the ability of VEGF to predict disease
progression and overall survival (OS) in HCC. This may be related
to differences in the methods of measuring and reporting
quantitative VEGF measurements. The three most commonly used
methods are serum-based VEGF quantitation using enzyme-
linked immunosorbent assay, tissue-based semi-quantitative VEGF
immunohistochemistry, and tissue-based mRNA measurement
(Sun and Tang, 2004). One argument against the use of serum
VEGF is the confounding role of platelets, which have been
reported to release VEGF into the blood (Banks et al, 1998; Webb
et al, 1998). A recent study, however, found that serum VEGF alone
correlated with hepatic tissue VEGF, suggesting that serum VEGF
is a useful indirect marker of tumour levels (Poon et al, 2003).
In this study, we sought to conduct a systematic review and
meta-analysis to estimate the prognostic importance of elevated
serum- and tissue-based VEGF levels for OS and disease-free
survival (DFS) among patients with HCC. A secondary goal of our
study was to consider the methodological quality of studies
examining tissue- and serum-based VEGF measurements.
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sMATERIALS AND METHODS
Literature search
A computer-aided literature search of PubMed (MEDLINE)
1950–present, MEDLINE in-process and non-indexed citations,
EMBASE, the Cochrane Library, DARE, and ACP Journal Club was
conducted. An initial search strategy using recognised search
terms ((VEGF or neovascularization) and ‘prognosis’ and ‘hepato-
cellular carcinoma’) was conducted in July 2007 and then repeated
in November 2007. Reference lists from identified primary studies
were then searched to identify any studies missed by the electronic
search strategies. Consultation with experts in the field was
performed to further identify additional published and unpub-
lished studies.
Study selection
Abstracts of all candidate articles were read by two independent
reviewers (DMK and SJS). Articles that could not be categorised
based on title and abstract alone were retrieved for full-text review.
These articles were independently read and checked for inclusion
criteria. Disagreements were resolved through consensus with a
third reviewer (JAT). Primary studies that reported data required
for meta-analysis were identified and included. Authors of
included studies were not contacted for additional, unreported
data.
Study inclusion/exclusion criteria
Inclusion criteria for primary studies were as follows: (1) proven
diagnosis of HCC in humans, (2) VEGF evaluation using either
serum- or tissue-based methods, and (3) correlation of VEGF with
OS or DFS. There was no pre-specified sample size or follow-up
period used to determine study inclusion. Language was not
restricted for abstract review, but was restricted to Western
languages for data collection. Studies not directly reporting hazard
ratios (HRs) were allowed if data were available for statistical
estimation as described below. All studies were carefully evaluated
to identify duplicate patient populations. Criteria used to
determine duplicate populations included study period, hospital,
treatment information, and any additional inclusion criteria.
Quality assessment of primary studies
Quality assessment was performed in each of the acceptable
studies in duplicate by independent reviewers (DMK and SJS)
using the Newcastle–Ottawa Quality Assessment Scale for cohort
studies (Table 1) (Wells et al, 2003). This scale is an eight-item
instrument that allows for assessment of patient population and
selection, study comparability, follow-up, and outcome of interest.
Interpretation of the scale is performed by awarding points, or
‘stars’, for high-quality elements. Stars are then added up and used
to compare study quality in a quantitative manner. Any
discrepancies were resolved by a consensus reviewer (JAT).
Data extraction
Two reviewers (DMK and SJS) independently extracted the
required information from all primary studies. Pre-specified data
elements included, but were not limited to, the following: (1)
demographic data regarding inclusion criteria, patient age, sex,
and treatment during follow-up; (2) tumour data including
number of primary lesions, size, stage, grade, vascular invasion,
and metastases; (3) survival data including OS and DFS; (4)
method of tissue VEGF measurement and semi-quantitative VEGF
levels; and (5) method of serum VEGF measurement and average
levels. Other variables included number of patients lost and
reasons for patients lost during follow-up. Our primary interest
was to gather data on OS, based on previously published
recommendations for clinical trial end points dealing with HCC
(Llovet et al, 2008). We did, however, also perform analyses on
DFS as this was commonly reported in the studies.
Data analysis/synthesis
After preliminary review of articles for study inclusion, inter-
reviewer agreement was assessed with the kappa statistic (Cohen,
1960). Included studies were then divided into two groups for
analysis: those with data regarding OS and those regarding DFS.
The primary outcome for analysis was survival in patients with
high VEGF values as compared to those with low VEGF values. For
serum-based studies, this took into consideration a reported cut-
off as determined by the authors of each study. Tissue studies
usually reported data in a binary fashion, interpreting the VEGF
value as either ‘high’ or ‘low.’ HRs with 95% confidence interval
Table 1 Newcastle–Ottawa quality assessment scale
a
Selection
(1) Representativeness of the exposed cohort
(a) Truly representative of the average ‘HCC patient’ in the community (1 star)
(b) Somewhat representative of the average ‘HCC patient’ in the community
(1 star)
(c) Selected group of users (e.g. nurses, volunteers)
(d) No description of the derivation of the cohort
(2) Selection of the non-exposed cohort
(a) Drawn from the same community as the exposed cohort (1 star)
(b) Drawn from a different source
(c) No description of the derivation of the non-exposed cohort
(3) Ascertainment of exposure (Proof of HCC and VEGF measurement)
(a) Secure record (eg surgical records) (1 star)
(b) Structured interview (1 star)
(c) Written self-report
(d) No description
(4) Demonstration that outcome of interest was not present at start of study
(a) Yes (1 star)
(b) No
Comparability
(1) Comparability of cohorts on the basis of the design or analysis
(a) Study controls for ‘metastasis or micrometastasis’ (1 star)
(b) Study controls for any additional factor (1 star) (Age, stage, grade etc.)
Outcome
(1) Assessment of outcome (Death or recurrence)
(a) Independent blind assessment (1 star)
(b) Record linkage (1 star)
(c) Self-report
(d) No description
(2) Was follow-up long enough for outcomes to occur? (Death or recurrence)
(a) Yes (‘2 years’) (1 star)
(b) No
(3) Adequacy of follow-up of cohorts
(a) Complete follow-up – all subjects accounted for (1 star)
(b) Subjects lost to follow-up unlikely to introduce bias – small number lost
‘(25%)’ or description provided of those lost (1 star)
(c) Follow-up rate ‘o75%’ and no description of those lost
(d) No statement
aA study can be awarded a maximum of one star for each numbered item within the
Selection and Outcome categories. A maximum of two stars can be given for
Comparability. Underlined and quoted phrases are provided in the scale to allow for
adjustment to particular studies. Italicised phrases indicate our interpretation of the
question relevant to this study.
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svalues were reported for individual studies, with an HR of greater
than 1 being associated with an adverse outcome. Where HRs were
not reported, a determination was made as to whether or not HR
estimation would be possible. To be eligible for HR estimation,
studies had to include the number of patients with high and low
VEGF levels, along with the number of observed deaths/cancer
recurrences. For studies that reported these data, mathematical HR
approximation was performed using established methods (Parmar
et al, 1998). In the case that sufficient data were not directly
available but a Kaplan–Meier curve was provided, data were
extracted from the survival curve and estimation of the HR was
then performed using the same method.
The heterogeneity of combined HRs was initially evaluated by
graphical examination of the Forrest plots. Statistical assessment
was then performed using a w
2-based test of homogeneity and
evaluation of the inconsistency index (I
2) statistic. The I
2 statistic
is defined as the percentage of variability due to heterogeneity
rather than chance with values 450% representing the possibility
for substantial heterogeneity (Higgins et al, 2003). Pooled
summary statistics for HRs of the individual studies were reported.
Owing to a priori assumptions about the likelihood for hetero-
geneity between primary studies, the random effects model of
DerSimonian and Laird (1986) was used for pooled analyses. A
P-value of less than 0.05 was chosen for significance.
Assessment of publication bias was performed for each of
the pooled study groups using the Egger’s bias indicator test
(Egger et al, 1997) defined by the following equation:
SND¼aþb s.e.(d)
–1. In this regression equation, SND is the
standard normal deviate defined by d (which represents HR)
divided by its standard error s.e.(d), a is the intercept, and b the
slope. The intercept value (a) provides an estimate of asymmetry
of the funnel plot, with positive values (a40) indicating a trend
towards higher HR values (ie decreased survival in patients
with high VEGF levels) in studies with smaller sample sizes. All
analyses were carried out using the statistical software Meta-DiSc
(version 1.1.1).
RESULTS
The abstracts and titles of 100 primary studies were identified for
initial review using search strategies as described. Reviewers
identified 26 potential studies for full-text review, with excellent
agreement between reviewers (k¼0.89). Upon further review, one
article was eliminated on the basis of language of publication and
another nine articles were eliminated due to inadequate data for
meta-analysis (Figure 1). Given that several authors have multiple
publications in this field, we took great care to ensure that data
reported in each paper were unique.
Quality assessment using the Newcastle–Ottawa Scale was
performed on all 16 studies included for meta-analysis. There
was a tendency towards higher methodological quality in the
serum VEGF studies as compared to the tissue studies (serum
mean score 5.5±1.2; tissue mean score 4.6±1.4), though this did
not reach statistical significance (P¼0.20). Of note, no study
attempted to control for other important prognostic factors that
may have confounded the association of high VEGF with survival.
Despite studies being performed at tertiary referral centres, nearly
all studies (15 of 16) were performed in Asia, with one study being
from Europe. Of the 16 included studies, 9 directly reported HRs;
however, back-calculation from available data using statistical
methods described above was necessary in 4 of 16 studies.
Estimation using survival curves was required in 3 of 16 studies.
During this process, data were segregated according to either OS or
DFS.
The characteristics of retained studies are listed in Table 2.
Studies are listed twice if they provided survival data for both DFS
and OS. In total, there were 554 patients in tissue studies and 679
patients in serum studies. The median sample size for all studies
was 71 patients (range¼36–120). The median sample size for
tissue studies was 60 patients whereas that for serum studies was
89 patients. The average age of all patients in 14 studies was 58
years (range¼50–66 years). This was similar in tissue (average 56
years) and serum (average 59 years) studies. The total proportion
of male subjects was around 75% in both tissue and serum studies.
Data on other important prognostic markers for HCC were
available in most studies. Viral hepatitis was usually reported and
was available for 92% of patients in tissue studies and 79% in
serum studies. Of the 16 studies, 13 reported the presence or
absence of cirrhosis, with approximately 75% of patients in all
studies having Child–Pugh class A or compensated disease.
Tumour size was described in most articles, but cut-offs for
large tumours varied as listed in Table 2. The percentage of
patients with large tumours was 48% in tissue studies and 33% in
serum studies. Multiple primary lesions were observed in 15% of
tissue and 23% of serum studies. Poor histological differentiation
was reported in 35% of tissue studies and 38% of serum studies.
Percentage of patients with vascular invasion was reported in half
of the studies, but tended to be higher in serum studies (59%;
range¼42–80%) as compared to tissue studies (44%; range¼
17–82%). Overall tumour stage was reported in only six studies,
but in nearly all cases VEGF levels were not determined based on
stage. Although most studies required a ‘curative’ resection or
treatment protocol for inclusion criteria, a number of patients
inevitably had evidence of micrometastasis or regional metastatic
disease on further evaluation. This was similar between studies,
with 18% patients in tissue VEGF studies having evidence of local,
regional, or diffuse metastatic disease as compared to 16% patients
in serum studies.
Hazard ratios were recorded for each of the included studies
using available data or the techniques described above. Individual
studies correlated a ‘high’ VEGF level with survival data. This
VEGF cut-off was chosen using different methods in each study.
Although some studies, such as many of the tissue studies, used a
purely binary system (positive or negative) for final analysis, other
studies used a quantitative system. Many of the quantitatively
based studies used the median level as a cut-off value. Still others
8 serum VEGF 8 tissue VEGF
16 studies available for
meta-analysis
9 without survival
data
1 in Chinese
74 out of scope
 = 0.89
26 candidate studies
100 studies identified using
described search strategies
Figure 1 Flow chart of the meta-analysis.
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ROC curve. The method used to determine the VEGF cut-off and
the number of patients above this threshold is further described in
Table 2.
Summary estimates of primary studies
Studies were divided into tissue and serum groups, with survival
analysis evaluating DFS and OS. In total, there were four tissue OS
studies (Chow et al, 1997; Jeng et al, 2004a; Deli et al, 2005; Sheen
et al, 2005), six tissue DFS studies (Jeng et al, 2004a; Sheen et al,
2005; Guo et al, 2006; Wada et al, 2006; Zhang et al, 2006; Ho et al,
2007), seven serum OS studies (Poon et al, 2001, 2004a,b, 2007;
Chao et al, 2003; Kim et al, 2004; Jeng et al, 2004b; Treiber et al,
2006), and five serum DFS studies (Poon et al, 2001, 2007; Chao
et al, 2003; Jeng et al, 2004b; Treiber et al, 2006). Pooled HRs were
then calculated for all groups.
For studies evaluating tissue VEGF levels in HCC, there did not
appear to be any major qualitative evidence for heterogeneity
between HRs as assessed by inspection of Forrest plots for either
DFS or OS (Figure 2). Increased tissue VEGF levels were
significantly correlated with OS with a pooled HR estimate of
2.15 (95% CI: 1.26–3.68). There was no evidence for heterogeneity
of the four available studies (I
2 statistic¼0%, P¼0.73). The
pooled HR estimate for DFS of the six tissue studies was 1.69 (95%
CI: 1.23–2.33), with no evidence for significant heterogeneity
between studies (I
2 statistic¼37.5%, P¼0.16).
Serum VEGF levels in HCC were also combined for analysis
relating high levels with DFS and OS. Inspection of Forrest plots
did not reveal substantial heterogeneity (Figure 3). OS in the serum
studies revealed a pooled HR of 2.35 (95% CI: 1.80–3.07). Again,
there was not a significant degree of heterogeneity between the
seven serum studies (I
2 statistic¼16.2%, P¼0.31). The pooled HR
estimate for DFS was 2.36 (95% CI: 1.76–3.16). There was no
heterogeneity between these five studies (I
2 statistic¼0%,
P¼0.76).
There was also no difference in analytic outcomes when
examining serum and tissue VEGF studies based on choice of
treatment (surgical vs non-surgical) for HCC (data not shown).
Assessment of publication bias
Visual assessment of a funnel plot provided no evidence of overt
publication bias for studies in each of the four pooled groups
(Figure 4). Formal evaluation using Egger’s test also failed to reveal
evidence for significant publication bias in tissue OS (P¼0.45) and
DFS (P¼0.56) studies. Similarly, there was no evidence for
significant publication bias in serum OS (P¼0.62) and DFS
(P¼0.69) studies.
DISCUSSION
There has been great interest in identifying prognostic markers for
patients with HCC as these markers can help guide clinical
decision-making regarding therapy and outcomes. To gain as
much information as possible, it is beneficial to study a variety of
prognostic measures using available demographics, pathological
characteristics, and biomarker studies. In this paper, we examine
the correlation of high levels of VEGF with OS after curative
treatment of HCC. From our systematic review and meta-analysis,
we identified and evaluated 16 primary studies from the published
literature (8 for tissue and 8 for serum) comparing survival data in
patients with high and low VEGF levels. Summary estimates
showed that both high tissue and serum VEGF correlated to OS as
well as DFS.
Quality assessment tools are being developed for prognostic
studies to help identify study bias and causes for heterogeneity
when performing meta-analysis. In this case, we chose to use the
Table 2 Summary table of the meta-analysis
Study
design
Treat-
ment
Number
of patients
(M/F)
Tumour
grade I/II
(III/IV)
Number
with
large
tumours
(cut-off
used; cm)
Number
with
multiple
primary
tumours
Study
quality
points
VEGF
detection
method
Survival
analysis
Hazard
ratios
Method to
determine
‘high’ VEGF
cut-off level
Number
of patients
with high
VEGF
Summary
results
Tissue-based studies
Guo et al, 2006 P S 90 (78/12) 65 (25) 53 (5) 15 6 of 9 Antibody DFS Reported in text X10% staining 69 Positive
Ho et al, 2007 C S 71 (52/19) 51 (19)* 23 (5) 6 4 of 9 Antibody DFS Estimated Median 35 Indeterminate
Jeng et al, 2004a C, P S 50 (31/19) 16 (34) 38 (3) 31 6 of 9 mRNA DFS Estimated NR 25 Positive
Sheen et al, 2005 C, P S 60 (35/25) 14 (36) 43 (3) 31 4 of 9 mRNA DFS Reported in text X0.500 49 Indeterminate
Wada et al, 2006 R S 60 (45/15) 33 (27) 33 (3) NR 3 of 9 Antibody DFS Survival curves Strong staining 12 Indeterminate
Zhang et al, 2006 R LT 82 (78/4) NR 42 (5) 32 3 of 9 Antibody DFS Reported in text 410% staining NR Indeterminate
Chow et al, 1997 R S 36 (32/4) 24 (3)* NR NR 5 of 9 Antibody OS Survival curves Any staining 13 Indeterminate
Deli et al, 2005 C, P S 105 (79/26) 92 (13) 34 (5) 0 6 of 9 Antibody OS Survival curves X60% stained 72 Indeterminate
Jeng et al, 2004a C, P S 50 (31/19) 16 (34) 38 (3) 31 6 of 9 mRNA OS Estimated NR 25 Positive
Sheen et al, 2005 C, P S 60 (35/25) 14 (36) 43 (3) 31 4 of 9 mRNA OS Reported in text X0.5 49 Indeterminate
Serum-based studies
Chao et al, 2003 C, P S 98 (91/7) 85 (13) 42 (5) 46 6 of 9 ELISA DFS Reported in text ROC curve NR Positive
Jeng et al, 2004b C, P S 50 (31/19) 16 (34) 38 (3) 31 6 of 9 mRNA DFS Estimated NR 25 Indeterminate
Poon et al, 2007 P RFA 120 (94/26) 14 (10)* 0 (5) 24 5 of 9 ELISA DFS Reported in text Median 60 Positive
Poon et al, 2001 C, P S 100 (76/24) 51 (49) 58 (5) NR 4 of 9 ELISA DFS Estimated Normal+2 s.d. 25 Indeterminate
Treiber et al, 2006 P Medical 71 (51/20) 48 (7)* NR NR 4 of 9 ELISA DFS Reported in text ROC curve NR Positive
Chao et al, 2003 C, P S 98 (91/7) 85 (13) 42 (5) 46 6 of 9 ELISA OS Reported in text ROC curve NR Positive
Jeng et al, 2004b C, P S 50 (31/19) 16 (34) 38 (3) 31 6 of 9 mRNA OS Estimated NR 25 Positive
Kim et al, 2004 Unclear Unclear 52 (39/13) NR 20 (5) NR 5 of 9 ELISA OS Reported in text NR 29 Indeterminate
Poon et al, 2007 P RFA 120 (94/26) 14 (10)* 0 (5) 24 5 of 9 ELISA OS Reported in text Median 60 Positive
Poon et al, 2004a C, P S 108 (76/32) 56 (52) 63 (5) 28 7 of 9 ELISA OS Reported in text Median 54 Positive
Poon et al, 2004b C, P TACE 80 (72/8) NR NR 30 7 of 9 ELISA OS Reported in text Median 40 Positive
Treiber et al, 2006 P Medical 71 (51/20) 48 (7)* NR NR 4 of 9 ELISA OS Reported in text ROC curve NR Indeterminate
Summary table of studies included in meta-analysis. Study design is described as consecutive patients (C), prospective (P), or retrospective (R). Treatment describes whether the
patients received curative surgical resection (S), transarterial chemoembolisation (TACE), radiofrequency ablation (RFA), or medical management of HCC. Tumour grade was
most often described using the Edmondson–Steiner grading system, but occasionally other systems were utilised. For this table, studies were grouped as well/moderate (I/II) or
poor (III/IV) degrees of differentiation. Incomplete data are indicated with an asterisk (*). Study quality is listed using the results of the Newcastle–Ottawa questionnaire
(Table 1). Summary results were either positive (95% CI above 1.0) or indeterminate (95% CI crossing 1.0). NR¼not reported.
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sNewcastle–Ottawa Quality Assessment Scale, which has been
validated for assessing nonrandomised case–control and cohort
studies with good inter-rater reliability (Wells et al, 2003). In this
meta-analysis, this scale allowed us to thoroughly consider the
most important aspects of each study that might confound the role
of high VEGF. In particular, we evaluated each study for the
representativeness of the patients with HCC, recorded whether the
study controlled for any key adverse prognostic factors (such as
micrometastasis or age) and evaluated whether there was adequate
follow-up over a long period. As this is a relatively new tool, there
is not much information about what score constitutes a high-
quality study vs a low-quality one. Therefore, we used this tool
principally for comparative purposes and identified that both
serum and tissue studies had features associated with the conduct
of quality prognostic studies. In our meta-analysis, serum-based
studies tended to be of slightly higher methodological quality than
tissue-based studies although this was not statistically significant.
When comparing the results of tissue- vs serum-based studies,
several key differences were observed. As discussed, both the study
characteristics of serum studies were of higher quality as compared
to tissue studies. Importantly, data from the serum VEGF studies
appear to be generalisable to all patients with HCC, as the included
populations were treated using a variety of curative therapies.
Although tissue studies only included surgically treated patients,
serum studies included patients treated with surgical or medical
management, chemoembolisation, or radiofrequency ablation.
When VEGF levels for both surgically and non-surgically treated
groups were examined, no difference was found between groups.
This suggests that choice of therapy was not potentially associated
with serum VEGF levels. Furthermore, it is recognised that many
factors contribute to the survival of patients with HCC, including
stage, extent of cirrhosis, and treatment methods. Unfortunately,
tumour stage data were not reliably reported in studies, so we
could make no determination of the influence of disease stage
related to VEGF level and OS. Typically, meta-regression would be
carried out to control for the most important factors affecting
survival. In this study, however, meta-regression techniques were
not performed due to the small number of primary studies
available for analysis.
It has been well documented that overall serum VEGF levels are
correlated with blood platelet levels (Poon et al, 2001, 2003; Kim
et al, 2004). To account for the variable influence on serum VEGF
level, it has been suggested that measuring the VEGF to platelet
ratio may be of value for determining the ‘true’ serum VEGF level
(Poon et al, 2001; Kim et al, 2004). The studies included in this
meta-analysis rarely reported data on platelet levels, and most did
not make an effort to control for platelet counts when calculating
survival data. However, even in the absence of this correction,
serum VEGF appears to be a reasonable indirect marker of overall
tissue VEGF levels (Poon et al, 2003). Importantly, seven of eight
serum studies reported using centrifugation and sample freezing
for VEGF determination. Similar collection methods have been
shown to minimise the contribution of platelet VEGF to overall
serum VEGF levels (Ferrero and Colombo, 2006).
Test for heterogeneity:
I2 = 0%, P = 0.73
Test for heterogeneity:
I2 = 37.5%, P = 0.16
100 10 5 2 1 0.5 0.2
* Ratio (95% confidence interval)
* Ratio (95% confidence interval)
Combined
Sheen et al (2005)
Jeng et al (2004a)
Deli et al (2005)
Chow et al (1997)
2.15 (1.26, 3.68)
2.38 (0.61, 9.22)
4.57 (1.04, 20.11)
1.89 (0.92, 3.86)
1.65 (0.41, 6.55)
10 5 2 1 0.5 0.2 0.1
Combined
Zhang et al (2006)
Wada et al (2006)
Sheen et al (2005)
Jeng et al (2004a)
Ho et al (2007)
Guo et al (2006) 1.83 (1.18, 2.83)
1.60 (0.56, 4.55)
2.83 (1.06, 7.54)
2.29 (0.65, 8.12)
1.67 (0.66, 4.23)
0.34 (0.10, 1.16)
1.69 (1.23, 2.33)
A
B
Figure 2 Forrest plots and meta-analysis of studies evaluating hazard ratios of high tissue VEGF levels as compared to low levels. Survival data are
reported as (A) disease-free survival (DFS) and (B) overall survival (OS).
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sOf 16 studies, 15 were performed using cohorts from medical
centres in Asia. Although not entirely unexpected given the high
burden of HCC in Asian populations (El-Serag, 2002), this raises a
question regarding external validity of results and applicability to
Western societies. However, multiple tissue (Jeng et al, 2004a;
Sheen et al, 2005; Ho et al, 2007) and serum (Poon et al, 2001,
2004a,b) studies failed to find a relationship between chronic viral
hepatitis status and VEGF levels. This is somewhat reassuring
given the high prevalence of this liver disease aetiology in Asia.
Notably, when controlling for important aetiological factors of
HCC, it has also been shown that overall patient survival is similar
across continents (Esnaola et al, 2003), suggesting that our results
could be applicable to various geographic populations.
Though we did not detect significant heterogeneity or publica-
tion bias between studies, it is important to note that because of
the small number of primary studies analysed in each group the
power to detect potentially important differences is limited.
Although we did not observe significant heterogeneity between
groups, heterogeneity was moderately high at 37.5% (P¼0.16) in
the tissue VEGF DFS group. This is most likely due to results from
the Zhang study, which evaluated disease recurrence in patients
who had undergone liver transplantation for HCC. Because the
entire liver is removed during the transplantation process, the
mechanisms for recurrence of the tumour may differ slightly.
Potential hypotheses to explain the difference in results with
this population include extrahepatic recurrence and immuno-
suppression. The relationship between VEGF production and these
two variables is not known and requires further study.
Publication bias remains a major problem in assessing the
validity of clinical research studies. Although the power to detect
publication bias is reduced when using a small number of primary
studies, Egger’s test was chosen for our investigation because of
the absence of significant heterogeneity between our primary
studies. In turn, we did not find evidence that publication bias may
be significantly influencing our results. We also focused on using
one statistical approach, as performing multiple tests can generate
discordant results that confuse data interpretation (Ioannidis and
Trikalinos, 2007). Several reports have emerged proposing
improvements in the reporting of prognostic studies of cancer
(McShane et al, 2005). Criteria including (1) blinded assessment of
prognostic marker to patient outcome, (2) prospective study
design, (3) study time period, (4) precise outcome definition, (5)
provision of candidate variable list, and (6) adequate description
and references for assay methods are now being recommended.
Future studies employing these quality criteria in a prospective
fashion are anticipated to determine the effects of improved
reporting (Kyzas et al, 2007).
With serum VEGF serving as an acceptable indirect marker of
tissue levels, the question remains whether to consider tissue
VEGF as a prognostic marker at all. At best, tissue VEGF is a
qualitative test that requires interpretation by a pathologist or
laboratory technician, which can be highly variable. Direct VEGF
Test for heterogeneity:
I2 = 16.2%, P = 0.31
Test for heterogeneity:
I2 = 0%, P = 0.76
100 10 5 2 1 0.5 0.2
* Ratio (95% confidence interval)
* Ratio (95% confidence interval)
Combined
Treiber et al (2006)
Poon et al (2004b)
Poon et al (2004a)
Poon et al (2007)
Kim et al (2004)
Jeng et al (2004b)
Chao et al (2003)
2.35 (1.80, 3.07)
1.72 (0.96, 3.57)
1.85 (1.10, 3.92)
2.64 (1.53, 4.55)
2.82 (1.47, 5.18)
0.77 (0.23, 2.63)
4.47 (1.02, 19.66)
3.44 (1.81, 6.57)
10 5 2 1 0.5
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Treiber et al (2006)
Poon et al (2001)
Poon et al (2007)
Jeng et al (2004b)
Chao et al (2003) 2.35 (1.26, 4.39)
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B
Figure 3 Forrest plots and meta-analysis of studies evaluating hazard ratios of high serum VEGF levels as compared to low levels. Survival data are
reported as (A) disease-free survival (DFS) and (B) overall survival (OS).
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sstaining is only performed on a small tissue sample, introducing
the possibility of sampling error given the heterogeneity in
angiogenesis distribution commonly seen in tumours. Further-
more, the examination of tissue requires an invasive biopsy that
can be costly. Although staining tumour tissue obtained at surgery
may be of some benefit, the advantage of serum VEGF is that it can
be easily drawn in a non-invasive fashion at any point in time after
curative treatment. Thus, there is no need for serial biopsies and
interpretation is more reliable given its quantitative nature.
On the basis of the results of this analysis, we believe serum
VEGF to be a more useful test than tissue VEGF for the prognosis
of HCC. Additional investigation is needed to characterise the
performance of serum VEGF as a prognostic tool in patients from
Europe and North America for assessing generalisability of results.
Future directions could also emphasise the identification of
optimal cut-points for high vs low VEGF levels, and determine
the contribution of underlying cirrhosis to both VEGF levels and
OS (Llovet et al, 2008). Although briefly discussed in one study
(Treiber et al, 2006), additional investigations evaluating serial
VEGF levels as a marker of disease progression or response to
therapy would be a valuable addition to the literature. In the
interim, this meta-analysis appears to initially support the
hypothesis that high levels of VEGF are associated with a reduced
probability of OS from HCC.
ACKNOWLEDGEMENTS
The authors would like to acknowledge the Mayo Clinic Center for
Translational Science Activities for partial funding of this research.
REFERENCES
Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ
(1998) Release of the angiogenic cytokine vascular endothelial growth
factor (VEGF) from platelets: significance for VEGF measurements and
cancer biology.[see comment]. Br J Cancer 77: 956–964
Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY,
Chan WK, Lee SD (2003) Prognostic significance of vascular endothelial
growth factor, basic fibroblast growth factor, and angiogenin in patients
with resectable hepatocellular carcinoma after surgery.[see comment].
Ann Surg Oncol 10: 355–362
Chow NH, Hsu PI, Lin XZ, Yang HB, Chan SH, Cheng KS, Huang SM, Su IJ
(1997) Expression of vascular endothelial growth factor in normal liver
and hepatocellular carcinoma: an immunohistochemical study. Hum
Pathol 28: 698–703
Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol
Meas 20: 37–46
Deli G, Jin CH, Mu R, Yang S, Liang Y, Chen D, Makuuchi M (2005)
Immunohistochemical assessment of angiogenesis in hepatocellular
carcinoma and surrounding cirrhotic liver tissues.[see comment]. World
J Gastroenterol 11: 960–963
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin
Trials 7: 177–188
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-
analysis detected by a simple, graphical test. BMJ 315: 629–634
El-Serag HB (2002) Hepatocellular carcinoma: an epidemiologic view.
J Clini Gastroenterol 35: S72–S78
Esnaola NF, Mirza N, Lauwers GY, Ikai I, Regimbeau JM, Belghiti J,
Yamaoka Y, Curley SA, Ellis LM, Nagorney DM, Vauthey JN (2003)
Comparison of clinicopathologic characteristics and outcomes after
resection in patients with hepatocellular carcinoma treated in the United
States, France, and Japan. Ann Surg 238: 711–719
Ferrero S, Colombo BM (2006) Differences between plasma and serum
vascular endothelial growth factor. Am J Cardiol 98: 424–425
Guo RP, Zhong C, Shi M, Zhang CQ, Wei W, Zhang YQ, Li JQ (2006)
Clinical value of apoptosis and angiogenesis factors in estimating the
3
Log(* ratio)
Log(* ratio) Log(* ratio)
Log(* ratio)
2 1 0 –1 1.9 1.5 1.1 0.7 0.3 –0.1 –0.5
0.5
0.4
0.3
0.2
s
.
e
.
s
.
e
.
0.8
0.6
0.4
0.2
s
.
e
.
s
.
e
.
Bias assessment plot Bias assessment plot
Bias assessment plot Bias assessment plot
3 2 1 0 –1 2.5 1.5 0.5 –0.5 –1.5
0.8
0.6
0.4
0.2
0.9
0.7
0.5
0.3
AB
CD
Figure 4 Bias assessment plots for studies included in all four meta-analyses. Plots are arranged as follows: (A) tissue VEGF disease-free survival, (B) tissue
VEGF overall survival, (C) serum VEGF disease-free survival, and (D) serum VEGF overall survival.
Prognostic value of VEGF in HCC
SJ Schoenleber et al
1391
British Journal of Cancer (2009) 100(9), 1385–1392 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sprognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol 132:
547–555
Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring
inconsistency in meta-analyses. BMJ 327: 557–560
Ho MC, Chen CN, Lee H, Hsieh FJ, Shun CT, Chang CL, Lai YT, Lee PH
(2007) Placenta growth factor not vascular endothelial growth factor A or
C can predict the early recurrence after radical resection of hepato-
cellular carcinoma. Cancer Lett 250: 237–249
Ioannidis JP, Trikalinos TA (2007) The appropriateness of asymmetry
tests for publication bias in meta-analyses: a large survey. CMAJ 176:
1091–1096
Jeng KS, Sheen IS, Wang YC, Gu SL, Chu CM, Shih SC, Wang PC, Chang
WH, Wang HY (2004a) Is the vascular endothelial growth factor
messenger RNA expression in resectable hepatocellular carcinoma of
prognostic value after resection? World J Gastroenterol 10: 676–681
Jeng KS, Sheen IS, Wang YC, Gu SL, Chu CM, Shih SC, Wang PC, Chang
WH, Wang HY (2004b) Prognostic significance of preoperative
circulating vascular endothelial growth factor messenger RNA expression
in resectable hepatocellular carcinoma: a prospective study. World J
Gastroenterol 10: 643–648
Kanda M, Nomoto S, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S,
Nakao A (2008) Correlations of the expression of vascular endothelial
growth factor B and its isoforms in hepatocellular carcinoma with
clinico-pathological parameters. J Surg Oncol 98(3): 190–196
Kim SJ, Choi IK, Park KH, Yoon SY, Oh SC, Seo JH, Choi CW, Kim BS, Shin
SW, Kim YH, Kim JS (2004) Serum vascular endothelial growth factor
per platelet count in hepatocellular carcinoma: Correlations with clinical
parameters and survival. Jpn J Clin Oncol 34: 184–190
Kyzas PA, Denaxa-Kyza D, Ioannidis JP (2007) Quality of reporting of
cancer prognostic marker studies: association with reported prognostic
effect. J Natl Cancer Inst 99: 236–243
Lam VW, Ng KK, Chok KS, Cheung T, Yuen J, Tung H, Tso W, Fan S, Poon
RT (2008) Risk factors and prognostic factors of local recurrence after
radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 207:
20–29
Li XM, Tang ZY, Zhou G, Lui YK, Ye SL (1998) Significance of vascular
endothelial growth factor mRNA expression in invasion and metastasis
of hepatocellular carcinoma. J Exp Clin Cancer Res 17: 13–17
Llovet JP, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX,
Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ (2008) Design
and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer
Inst 100: 698–711
Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP (2007)
Prognostic molecular markers in hepatocellular carcinoma: a systematic
review. Eur J Cancer 43: 979–992
Marrero JA (2006) Hepatocellular carcinoma. Curr Opin Gastroenterol 22:
248–253
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM
(2005) Reporting recommendations for tumor marker prognostic studies
(REMARK). J Natl Cancer Inst 97: 1180–1184
Pang R, Poon RT (2006) Angiogenesis and antiangiogenic therapy in
hepatocellular carcinoma. Cancer Lett 242: 151–167
Parkin DM (2001) Global cancer statistics in the year 2000 [erratum
appears in Lancet Oncol 2001; 2(10): 596]. Lancet Oncol 2: 533–543
Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics
to perform meta-analyses of the published literature for survival
endpoints [erratum appears in Stat Med 2004; 23(11): 1817]. Stat Med
17: 2815–2834
Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST (2004a) Prognostic
significance of serum vascular endothelial growth factor and endostatin
in patients with hepatocellular carcinoma. Br J Surg 91(10): 1354–1360
Poon RT, Lau C, Yu WC, Fan ST, Wong J (2004b) High serum levels of
vascular endothelial growth factor predict poor response to transarterial
chemoembolization in hepatocellular carcinoma: a prospective study.
Oncol Rep 11(5): 1077–1084
Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST (2003) Quantitative
correlation of serum levels and tumor expression of vascular endothelial
growth factor in patients with hepatocellular carcinoma. Cancer Res 63:
3121–3126
Poon RTP, Lau C, Pang R, Ng KK, Yuen J, Fan ST (2007) High
serum vascular endothelial growth factor levels predict poor
prognosis after radiofrequency ablation of hepatocellular carcinoma:
importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14:
1835–1845
Poon RTP, Ng IOL, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J (2001)
Serum vascular endothelial growth factor predicts venous invasion in
hepatocellular carcinoma: a prospective study. Ann Surg 233: 227–235
Sheen IS, Jeng KS, Shih SC, Kao CR, Chang WH, Wang HY, Wang PC,
Wang TE, Shyung LR, Chen CZ (2005) Clinical significance of the
expression of isoform 165 vascular endothelial growth factor mRNA in
noncancerous liver remnants of patients with hepatocellular carcinoma.
World J Gastroenterol 11: 187–192
Sun H, Tang Z (2004) Angiogenesis in hepatocellular carcinoma: the
retrospectives and perspectives. J Cancer Res Clin Oncol 130: 307–319
Treiber G, Wex T, Rocken C, Fostitsch P, Malfertheiner P (2006) Impact of
biomarkers on disease survival and progression in patients treated with
octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin
Oncol 132: 699–708
Tsai TJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Hsia CY, Wu CW
(2000) Clinical significance of microscopic tumor venous invasion in
patients with resectable hepatocellular carcinoma [see comment].
Surgery 127: 603–608
Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Nakamura M,
Yoshioka S, Kato H, Damdinsuren B, Tang D, Marubashi S, Miyamoto A,
Takeda Y, Umeshita K, Nakamori S, Sakon M, Dono K, Wakasa K,
Monden M (2006) Expression pattern of angiogenic factors and
prognosis after hepatic resection in hepatocellular carcinoma: impor-
tance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int
26(4): 414–423
Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE (1998) Vascular
endothelial growth factor (VEGF) is released from platelets during blood
clotting: implications for measurement of circulating VEGF levels in
clinical disease. Clin Sci 94: 395–404
Wells GA, Brodsky L, O’Connell D, Shea B, Henry D, Mayank S, Tugwell P
(2003) An Evaluation of the Newcastle Ottawa Scale: An Assessment Tool
for Evaluating the Quality of Non-Randomized Studies. In XI Cochrane
Colloquium Vol. O-63. p 26. Barcelona: XI International Cochrane
Colloquium Book of Abstracts
Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, Xu J, Qian F, Chen ZN
(2006) CD147, MMP-2, MMP-9 and MVD-CD34 are significant
predictors of recurrence after liver transplantation in hepatocellular
carcinoma patients. Cancer Biol Ther 5: 808–814
Zhou L, Rui JA, Wang SB, Chen SG, Qu Q, Chi TY, Wei X, Han K, Zhang N,
Zhao HT (2007) Factors predictive for long-term survival of male
patients with hepatocellular carcinoma after curative resection. J Surg
Oncol 95: 298–303
Prognostic value of VEGF in HCC
SJ Schoenleber et al
1392
British Journal of Cancer (2009) 100(9), 1385–1392 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s